)
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Need to develop education system, ensure youth no longer forced to study abroad, says PM Modi
A drop of 20% and 40% was reported in laboratory tests and radiological interventions like X-rays and CT scans, respectively
The company reported 9 per cent on-year increase in its average revenue per occupied bed (Arpob) at Rs 30,551 in Q1FY25, with bed occupancy rising to 61 per cent in Q1 from 51 per cent last year
Officials from Delhi along with forensic scientists to reach Bengal's capital today
The firm's revenue from operations rose to Rs 2,093 crore, a 32 per cent rise from Rs 1,585 crore reported in Q1FY24
Protests by doctors demanding justice and better workplace security began in Kolkata and eventually spread to other parts of the country
Commenting on the results, Ameera Shah, Executive Chairperson and Whole-time Director, Metropolis Healthcare, said that the company has consistently achieved high growth in patient volume
A senior official in the health ministry said that the rule will help to make available essential drugs that have a significant therapeutic advance over the current standard care
A separate marketing practices code has been a long-standing demand for medical devices. Currently, the industry has to comply with the marketing practices code for pharmaceuticals
The company's revenue from operations rose to Rs 602 crore in Q1FY25, an 11.3 per cent Y-o-Y growth from Rs 541 crore reported in Q1FY24
"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report
With just four days for the closing ceremony of the Paris Games, India stares at the possibility of returning home with few medals
The company's revenue from operations rose to Rs 1,859 crore in Q1FY25, a 12.2 per cent Y-o-Y rise from Rs 1,657 crore reported in Q1FY24
The decrease in the group's consolidated Ebitda margin is being attributed to the negative Ebitda reported by Cenexi, its recent acquisition
The lesser numbers in Telangana are due to the presence of the state's own health insurance scheme for the poor, 'Aarogyasri,' which later merged with AB-PMJAY only in 2021
Asks Centre's high-level committee to review NTA's ops and recommend reforms
Over 400 drug manufacturing units, including MSMEs, inspected after high frequency of NQS reports
GSK Pharma's stocks were up by 2.49 per cent, ending the day's trade at Rs 2,824.45 apiece on the Bombay Stock Exchange (BSE)
On a sequential basis, the company exhibited a 6.8 per cent rise in net profit, while its revenue grew by 5.5 per cent, from Rs 2,655 crore and Rs 12,380.7 crore reported in Q3 FY24, respectively
Max to invest Rs 230 crore to set up 250 bed hospital in Mohali